Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SEPN
HOLDSepterna, Inc. · Healthcare · United States · $1.5B · Avg Vol: $17M/d
COMPANY DESCRIPTION
Septerna, Inc. is a biotechnology company focused on discovering and developing novel small molecule medicines targeting G protein-coupled receptors (GPCRs). It leverages a proprietary drug discovery platform designed to identify new small molecule candidates for challenging GPCR targets, aiming to address unmet medical needs. Septerna is a clinical-stage biotechnology company with a specialized focus on GPCR drug discovery, utilizing a unique platform to unlock new therapeutic avenues.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0.2M | 1.1M | 46.0M | 1644.5% | 72.3M | 76.9M | 65.8M | 19.7% |
| EPS | -1.42 | 0.03 | -7.26 | -1.10 | — | -0.77 | -1.84 | -2.66 | — |
| Shares | 42.0M | 42.0M | 44.4M | 44.8M | +6.7% | 45.1M | — | — | — |
| Debt | 0.7M | 12.6M | 25.5M | 23.6M | 221.6% | 23.1M | — | — | — |
| Equity | -44.2M | -38.4M | 420.0M | 381.9M | -9.1% | — | — | — | — |
| Op CF | -23.3M | -38.7M | -67.5M | 110.2M | — | 107.9M | — | — | — |
| Inv CF | -1.3M | 22.1M | -160.6M | -229.4M | — | — | — | — | — |
| Fin CF | 30.1M | 74.5M | 377.8M | 1.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SEPN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SEPN | Septerna, Inc.(you) | $1.5B | 36 | HOLD |
| SRPT | Sarepta Therapeutics, Inc. | $1.7B | 36 | HOLD |
| VIR | Vir Biotechnology, Inc. | $1.5B | 32 | SELL |
| NVAX | Novavax, Inc. | $1.2B | 37 | HOLD |
| DMRA | Damora Therapeutics, Inc. | $1.8B | 34 | SELL |
| ADMA | ADMA Biologics, Inc. | $1.9B | 35 | HOLD |
| XNCR | Xencor, Inc. | $1.4B | 30 | SELL |
| JBIO | Jade Biosciences, Inc. | $1.2B | 33 | SELL |
| BCAX | Bicara Therapeutics Inc. | $1.8B | 32 | SELL |
| AVBP | ArriVent BioPharma, Inc. | $1.5B | 29 | SELL |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%